Mesenteric Lymphadenitis

Back

Background

Mesenteric lymphadenitis refers to inflammation of the mesenteric lymph nodes. This process may be acute or chronic, depending on the causative agent. It causes a clinical presentation that is often difficult to differentiate from acute appendicitis.[1]

Pathophysiology

Microbial agents are thought to gain access to the lymph nodes via the intestinal lymphatics. Organisms subsequently multiply and, depending on the virulence of the invading pathogen, elicit varying degrees of inflammation and, occasionally, suppuration.

Grossly, the lymph nodes are enlarged and often soft. The adjourning mesentery may be edematous, with or without exudates. If a contiguous primary source of infection (eg, the appendix) is present, evidence of inflammation is often apparent.

Microscopically, the lymph nodes show nonspecific hyperplasia and, in suppurative infection, necrosis with numerous pus cells.

Epidemiology

Frequency

United States

The true incidence of this disease is not known, because it can be easily missed or mistaken for other diagnoses. The condition is generally thought to be common. Up to 20% of patients undergoing appendectomy have been found to have nonspecific mesenteric adenitis.

International

Frequency is similar to that of the United States. Yersinia enterocolitica infection has a geographic variation. This infection is most common in the temperate countries of Europe, North America, and Australia; it has been particularly noted in Eastern Europe.

Mortality/Morbidity

Mesenteric lymphadenitis generally is a benign disease, but patients with sepsis may have a fatal outcome.

Sex

The condition affects males and females equally. Yersinia infection is more common in boys than in girls.

Age

Mesenteric lymphadenitis can occur in adults but is more common in children and adolescents younger than 15 years, and this condition during childhood or adolescence is linked to a significantly reduced risk of ulcerative colitis in adulthood.[2]

Frisch et al reviewed Swedish and Danish cohort studies involving 709,353 patients who had undergone appendicectomy and were followed up for subsequent ulcerative colitis to determine the role of appendicitis and mesenteric lymphadenitis in the risk of ulcerative colitis following appendicectomy.[2] The investigators also studied the impact of appendicectomy in 224,483 patients with a family history (parents or siblings) of inflammatory bowel disease and found that regardless of familial predisposition to inflammatory bowel disease, appendicitis and mesenteric lymphadenitis during childhood or adolescence is linked to a significantly reduced risk of ulcerative colitis in adulthood.[2]

History

Onset and progression may be insidious or sometimes dramatic. Clinical features of associated organ involvement, such as enterocolitis or ileitis in Yersinia infection, may be present. Clinical presentations include the following:

Physical

No set of physical findings is pathognomonic of mesenteric lymphadenitis.

Causes

Laboratory Studies

Imaging Studies

Procedures

Medical Care

The objective of medical management is to quickly identify patients who require surgical intervention (ie, for appendicitis) and to refer appropriately. Empiric, broad-spectrum antibiotics may be used in moderately to severely ill patients and should cover Yersinia strains, commonly causative in mesenteric adenitis. General supportive care includes hydration and pain medication after excluding acute surgical abdomen. Patients with mild, uncomplicated presentations do not require antibiotics, and supportive care generally suffices.

Surgical Care

Consultations

Make early contact with a general surgeon while evaluating the patient to exclude etiologies that require urgent surgery.

Diet

No particular diet is recommended. Temporary withholding of oral intake may be necessary while nausea and vomiting resolve and initially until a definitive diagnosis is confirmed.

Activity

No restriction of activity is required.

Medication Summary

Antibiotics are often started empirically in moderately to severely ill patients, using broad-spectrum antibiotics intended to cover the commonly associated pathogens. Antibiotic treatment should then be adjusted based on the sensitivity of the isolated pathogen. Treatment duration is variable based on the cause and severity of illness. For uncomplicated cases, antibiotic treatment is not necessary.

Metronidazole (Flagyl, Protostat)

Clinical Context:  Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Exerts a bactericidal effect by inhibiting protein synthesis. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis).

Clindamycin (Cleocin)

Clinical Context:  Lincosamide used for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, thus causing cessation of RNA-dependent protein synthesis.

Ampicillin (Omnipen, Polycillin)

Clinical Context:  Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication orally.

Amoxicillin (Amoxil, Trimox)

Clinical Context:  Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.

Ciprofloxacin (Cipro)

Clinical Context:  Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, Staphylococcus epidermidis, and most gram-negative organisms but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth. Trovafloxacin (Trovan) overcomes many of these limitations. Continue treatment for at least 2 d (7-14 d typical) after signs and symptoms have disappeared.

Imipenem/cilastin (Primaxin)

Clinical Context:  For treatment of multiple organism infections in which other agents do not have wide-spectrum coverage or are contraindicated because of potential for toxicity.

Cefoxitin (Mefoxin)

Clinical Context:  Second-generation cephalosporin indicated for gram-positive cocci and gram-negative rod infections. Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin.

Ticarcillin/clavulanate (Timentin)

Clinical Context:  Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive bacteria, most gram-negative bacteria, and most anaerobes.

Ampicillin/sulbactam (Unasyn)

Clinical Context:  Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Class Summary

When indicated, empiric antimicrobial therapy must be comprehensive and should cover the likely pathogens in the context of the clinical setting. Given the predominance of Y enterocolitica, initial antibiotic selection from trimethoprim-sulfamethoxazole (TMP-SMX), third-generation cephalosporins, fluoroquinolones, aminoglycosides, and doxycycline should be considered. These agents provide broad coverage for enteric pathogens.

Further Inpatient Care

Further Outpatient Care

Complications

Prognosis

Author

Jennifer Lynn Bonheur, MD, Attending Physician, Division of Gastroenterology, Lenox Hill Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Mukul Arya, MD, Associate Professor of Internal Medicine, Assistant Director of Therapeutic Endoscopy, Department of Gastroenterology and Internal Medicine, Wyckoff Heights Medical Center/Weill Medical College

Disclosure: Nothing to disclose.

Norvin Perez, MD, Medical Director, Juneau Urgent and Family Care

Disclosure: Nothing to disclose.

Oluyinka S Adediji, MD, Consulting Staff, Department of Adult and General Medicine, Health Services Incorporated, Montgomery, Alabama

Disclosure: Nothing to disclose.

Specialty Editors

Vivek V Gumaste, MD, Associate Professor of Medicine, Mount Sinai School of Medicine of New York University; Adjunct Clinical Assistant, Mount Sinai Hospital; Director, Division of Gastroenterology, City Hospital Center

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Douglas M Heuman, MD, FACP, FACG, AGAF, Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Alex J Mechaber, MD, FACP, Senior Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD, Clinical Professor of Medicine, Drexel University College of Medicine

Disclosure: Nothing to disclose.

References

  1. Toorenvliet B, Vellekoop A, Bakker R, Wiersma F, Mertens B, Merkus J, et al. Clinical differentiation between acute appendicitis and acute mesenteric lymphadenitis in children. Eur J Pediatr Surg. Mar 2011;21(2):120-3. [View Abstract]
  2. Frisch M, Pedersen BV, Andersson RE. Appendicitis, mesenteric lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. BMJ. Mar 9 2009;338:b716. [View Abstract]
  3. Ackerman SJ, Irshad A, Anis M. Ultrasound for pelvic pain II: nongynecologic causes. Obstet Gynecol Clin North Am. Mar 2011;38(1):69-83, viii. [View Abstract]
  4. Arrese M, Lopez F, Rossi R. Extrahepatic cholestasis attributable to tuberculous adenitis. Am J Gastroenterol. May 1997;92(5):912-3. [View Abstract]
  5. Asch MJ, Amoury RA, Touloukian RJ. Suppurative mesenteric lymphadenitis. A report of two cases and review of the literature. Am J Surg. Apr 1968;115(4):570-3. [View Abstract]
  6. Blattner RJ. Acute mesenteric lymphadenitis. J Pediatr. Mar 1969;DA - 19690327(3):479-81. [View Abstract]
  7. Campbell GL, Dennis TD. Plague and Other yersinia infections. In: Fauci AS et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill;1998:975-983.
  8. Currie B. Yersinia enterocolitica. Pediatr Rev. Jul 1998;19(7):250; discussion 251. [View Abstract]
  9. Daly JM, Adams JT, et al. Abdominal wall, Omentum, Messentery and Retroperitoneum. In: Schwarttz ST et al, eds. Principles of Surgery. 7th ed. New York, NY: McGraw-Hill Health Professions Div;1999:1574-1575.
  10. Faller DV. Diseases of Lymph nodes and Spleen. In: Bennet JC et al, eds. Cecil Textbook of Medicine. WB Saunders;1996:1968-970.
  11. Kelly CS, Kelly RE Jr. Lymphadenopathy in children. Pediatr Clin North Am. Aug 1998;45(4):875-88. [View Abstract]
  12. Morris Jr JG. Yersinia infections. In: Bennet JC et al, eds. Cecil textbook of Medicine. WB Saunders;1996:1661.
  13. Rao PM, Rhea JT, Novelline RA. CT diagnosis of mesenteric adenitis. Radiology. 1997;202:145-149.
  14. Schrock TR. Appendicitis. Gastrointestinal and Liver Disease, 6th Edition. 1998;1782.
  15. Sivit CJ. Imaging children with acute right lower quadrant pain. Pediatr Clin North Am. Jun 1997;44(3):575-89. [View Abstract]
  16. Zganjer M, Roic G, Cizmic A. Infectious ileocecitis--appendicitis mimicking syndrome. Bratisl Lek Listy. 2005;106(6-7):201-2.